icad Inc ICAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICAD is a good fit for your portfolio.
News
-
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
-
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
-
iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution
-
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
-
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
-
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
-
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
-
Icad Rises on Google Health Development Deal
Trading Information
- Previous Close Price
- $1.66
- Day Range
- $1.65–1.77
- 52-Week Range
- $1.05–3.97
- Bid/Ask
- $1.68 / $1.81
- Market Cap
- $44.27 Mil
- Volume/Avg
- 193,862 / 159,605
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.23
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 109
- Website
- https://www.icadmed.com
Valuation
|
Metric
|
ICAD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.42 |
Price/Sales | 2.23 |
Price/Cash Flow | — |
Price/Earnings
ICAD
Financial Strength
|
Metric
|
ICAD
|
|---|---|
Quick Ratio | 2.10 |
Current Ratio | 2.83 |
Interest Coverage | −2,657.80 |
Quick Ratio
ICAD
Profitability
|
Metric
|
ICAD
|
|---|---|
Return on Assets (Normalized) | −19.81% |
Return on Equity (Normalized) | −29.37% |
Return on Invested Capital (Normalized) | −28.99% |
Return on Assets
ICAD
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ABT
| Abbott Laboratories | Zjktgf | $181.2 Bil | |
SYK
| Stryker Corp | Krtp | $110.4 Bil | |
MDT
| Medtronic PLC | Vwgv | $104.8 Bil | |
BSX
| Boston Scientific Corp | Qvwtyv | $80.4 Bil | |
DXCM
| DexCom Inc | Gmvr | $44.7 Bil | |
EW
| Edwards Lifesciences Corp | Xjmyz | $41.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Zcchd | $24.2 Bil | |
PHG
| Koninklijke Philips NV ADR | Ryhrw | $18.6 Bil | |
ALGN
| Align Technology Inc | Ffgxxgj | $16.5 Bil | |
PODD
| Insulet Corp | Fbdsb | $13.3 Bil |